Satellos Bioscience Inc.
MSCL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 9.64M | 7.31M | -11.46M | 3.99M | 4.44M |
| Gross Profit | -9.64M | -7.31M | 11.46M | -3.99M | -4.44M |
| SG&A Expenses | 2.53M | 2.73M | 2.19M | 1.97M | 1.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.17M | 10.04M | 7.65M | 5.97M | 6.37M |
| Operating Income | -12.17M | -10.04M | -7.65M | -5.97M | -6.37M |
| Income Before Tax | -11.67M | -9.74M | -7.25M | -5.80M | -5.58M |
| Income Tax Expenses | 44.00K | 33.00K | 58.00K | 19.00K | 32.00K |
| Earnings from Continuing Operations | -11.72M | -9.77M | -7.30M | -5.82M | -5.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.72M | -9.77M | -7.30M | -5.82M | -5.61M |
| EBIT | -12.17M | -10.04M | -7.65M | -5.97M | -6.37M |
| EBITDA | -12.16M | -10.04M | -7.65M | -5.96M | -6.37M |
| EPS Basic | -0.56 | -0.53 | -0.47 | -0.42 | -0.39 |
| Normalized Basic EPS | -0.35 | -0.33 | -0.29 | -0.26 | -0.24 |
| EPS Diluted | -0.56 | -0.53 | -0.47 | -0.42 | -0.39 |
| Normalized Diluted EPS | -0.35 | -0.33 | -0.29 | -0.26 | -0.24 |
| Average Basic Shares Outstanding | 20.83M | 18.44M | 15.47M | 13.94M | 14.27M |
| Average Diluted Shares Outstanding | 20.83M | 18.44M | 15.47M | 13.94M | 14.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |